Principal Investigator
David Michael Miller
Education
Fellowship in Hematology/Oncology
- Beth Isreal Deaconess Medical Center
- 2015-2018
Oncology Center for Excellence Fellowship
- Food and Drug Administration
- 2018
Residency
Internal Medicine
- Brigham and Women’s Hospital
- 2010, 2015
Dermatology
- Columbia University Medical Center
- 2011 - 2014
Doctorate of Medicine
- University of Massachusetts Medical School
- 2002-2010
PhD in Biomedical Sciences
- University of Massachusetts Medical School
- 2004-2008
BA in Political Science
- Boston College
- 1996 - 2000
Biography
David Michael Miller, MD, PhD, FAAD is a Board-Certified Dermatologist, Internist and Medical Oncologist at Massachusetts General Hospital and investigator in the Massachusetts General Hospital Cancer Center. The Miller Lab’s long-term goal is to identify and develop novel therapeutics for advanced skin cancer and to understand the mechanism of response and resistance to those therapies.
Dr. Miller graduated with Honors from Boston College where he earned a BA in Political Science. He received his medical (MD) and PhD degree in Biomedical Sciences from the University of Massachusetts. While at UMass, Dr. Miller received the American Diabetes Association Physician-Scientist Training Award, a Fuller Foundation grant, and he was inducted into the Alpha Omega Honor Society.
He then completed a Dermatology residency at Columbia University Medical Center, followed by a residency in Internal Medicine at Brigham and Women’s Hospital. Following both residencies, Dr. Miller completed fellowship training in Hematology/Oncology at Beth Israel Deaconess Medical Center and in the Oncology Center of Excellence at the Food and Drug Administration.
Dr. Miller is one of the very few clinicians in the country who is board certified in Internal Medicine, Dermatology and Medical Oncology. He currently practices both Dermatology and Medical Oncology in the Massachusetts General Hospital Cancer Center and at Massachusetts Eye and Ear Infirmary, where he is the Director of the Center for Merkel Cell Carcinoma. Dr. Miller also co-directs multi-discliplinary clinics in advanced skin cancer at both MGH and MEEI.
Dr. Miller belongs to several professional organizations, including the American Academy of Dermatology, Medical Dermatology Society, and the American Society of Clinical Oncology. He has numerous peer-reviewed publications and he has presented his work at the Society for Investigative Dermatology, New York Academy of Medicine, the American Academy of Dermatology, and the U.S. FDA. He is also a reviewer for the British Journal of Dermatology, Journal of Investigative Dermatology, JAEDV, and Clinical Cancer Research.
Due to his expertise in Merkel Cell Carcinoma and Squamous Cell Carcinoma, Dr. Miller has also served on advisory boards to several pharmaceutical companies, including Pfizer, Merck, Regeneron and Sanofi Genzyme.
The Miller Lab’s research portfolio consists of clinical and translational projects in Merkel Cell carcinoma, cutaneous Squamous Cell Carcinoma and Melanoma. Dr. Miller has received support for his research from the NIH in the form of a loan repayment award, a Research Grant from the American Skin Association, the Paul Carbone, MD fellowship award from ECOG-ACRIN, and the Mentoring Award in Oncology, Advanced Analytics and Regulatory Science from Project Data Sphere.
Board Certifications
Dermatology, American Board of Dermatology
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine